Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Aprilbio Co., Ltd. is a company in the Biotechnology & Pharmaceuticals technology area. The portfolio currently includes 1 pending office action. This 1 pending office action is assigned to 1 distinct art unit, which shows a singular technical focus for the company's current prosecution.
The prosecution is being conducted by 1 distinct examiner, SZPERKA, MICHAEL EDWARD. This busiest examiner is responsible for 1 pending office action, which is the only active case for the company. SZPERKA, MICHAEL EDWARD is therefore the primary individual overseeing the company's current patent office matters.
With 1 distinct examiner and 1 distinct art unit, the prosecution is highly concentrated. Practitioners should be aware that the outcome of the pending matter relies on the specific feedback from SZPERKA, MICHAEL EDWARD. This focus on 1 art unit suggests that the company's current biotechnology technology is being evaluated within a very specific technical framework.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| §112 only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SZPERKA, MICHAEL EDWARD | 1 | 62.9% | +36.8% |
| ROONEY, NORA MAUREEN | 1 | 60.3% | +23.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18246423 | Recombinant Fusion Proteins Comprising Interleukin-18-Binding Protein and Antigen Binding Fragment to Serum Albumin, and Compositions and Uses Thereof | SZPERKA, MICHAEL EDWARD | 5d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18246423 | Recombinant Fusion Proteins Comprising Interleukin-18-Binding Protein and Antigen Binding Fragment to Serum Albumin, and Compositions and Uses Thereof | SZPERKA, MICHAEL EDWARD | 5d overdue |
| 17759313 | MULTISPECIFIC ANTIBODIES, COMPOSITIONS COMPRISING THE SAME, AND VECTORS AND USES THEREOF | ROONEY, NORA MAUREEN | — |
| Art Unit | Apps |
|---|---|
| 1641 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18246423 | Recombinant Fusion Proteins Comprising Interleukin-18-Binding Protein and Antigen Binding Fragment to Serum Albumin, and Compositions and Uses Thereof | SZPERKA, MICHAEL EDWARD | 1641 | §101§103Other | Final Rejection | 5d overdue | Pending | Mar 23, 2023 |
| 17759313 | MULTISPECIFIC ANTIBODIES, COMPOSITIONS COMPRISING THE SAME, AND VECTORS AND USES THEREOF | ROONEY, NORA MAUREEN | 1641 | §112 | Non-Final OA | — | Pending | Jul 22, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial